- ISIN DE0006599905
- Land Deutschland
Merck KGaA
Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide
|
Merck KGaA / Key word(s): Study results Darmstadt, 5 December 2023: Merck KGaA is investigating a highly selective oral and central nervous system penetrant Bruton’s tyrosine kinase inhibitor (BTKi) as a potential treatment for relapsing multiple sclerosis (“RMS“) in two pivotal phase III clinical trials (evolutionRMS 1 and evolutionRMS 2, together the “Clinical Trials“). Both Clinical Trials, evaluating the efficacy and safety of evobrutinib compared to teriflunomide for up to 156 weeks, did not meet the primary endpoint of reducing annualized relapse rates (ARR) in people with RMS.
Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world. Contact: Esther Döringer Merck KGaA Frankfurter Straße 250 64293 Darmstadt Germany Phone: +49 151 1454 7809 Email: esther.doeringer@merckgroup.com Internet: https://www.merckgroup.com/en ISIN: DE0006599905 WKN: 659990 Indices: DAX Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX End of Inside Information
05-Dec-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Merck KGaA |
| Frankfurter Str. 250 | |
| 64293 Darmstadt | |
| Germany | |
| Phone: | +49 (0)6151 72 – 2702 |
| E-mail: | Friederike.Segeberg@merckgroup.com |
| Internet: | https://www.merckgroup.com/de |
| ISIN: | DE0006599905 |
| WKN: | 659990 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX |
| EQS News ID: | 1790011 |
| End of Announcement | EQS News Service |
Aktuelle News
Aktuelle Berichte
Anstehende Events
Events Funktionen
Weitere Funktionen
Webcasts
Keine Webcasts gefunden